ABBV

Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.

Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

Market Domination Overtime Host Jared Blikre keeps track of several stocks moving in extended-hours trading after releasing earnings results, including AstraZeneca (AZN), AbbVie (ABBV), and Kenvue (KVUE).

LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook.

AbbVie (ABBV) raised its 2026 guidance on Friday as the biopharmaceutical company's immunology and n

AbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.

AbbVie just handed shareholders their latest raise while your CD rate sits frozen, but the comparison between a guaranteed payment and a growing dividend gets complicated fast once taxes, price swings, and reinvestment risk enter the picture.

Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non-GAAP profit of $3.82 per share was 1.3% above analysts’ consensus estimates.

AbbVie stock slipped slightly Friday, but the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi.